Allogeneic SCT remains the only curative option for Multiple Myeloma. However, conventional transplants remain associated with a substantial transplant related mortality which compromises effectiveness in younger patients and precludes their use entirely in patients over the age of 55 years. The tolerability and remarkable activity of lenalidomide against myeloma makes it an excellent candidate to be used in an adjunctive role early after a reduced intensity regimen transplant prior to later institution of DLI, to suppress the growth and rapid recovery of a residual myeloma cell population.
Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
Chief Investigator: Dr Mark Cook
|
|
Sponsor: University Hospitals Birmingham NHS Foundation Trust
|
|
Funders: CRUK Feasibility Study Committee. Educational grant provided by Celgene Ltd
|
|
Disease Site: Multiple myeloma (Leukaemia)
|
|
Trial Type: Clinical Trial of an Investigational Medicinal Product
|
|
Status: Closed
|
|
UKCRN Study ID: 7268
|
|
Open to new sites? No
|
|
Recruitment start date: 31/05/2011
|
|
Anticipated Recruitment end date: N/A- closed to recruitment
|
|
CRCTU Trial Management Team: Haematology
|
|
Trial E-mail Address: LenaRIC@trials.bham.ac.uk
|
|